(PGEN) Precigen - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.483m USD | Total Return: 205% in 12m
Avg Turnover: 12.1M
Qual. Beats: 0
Rev. Trend: 11.0%
Qual. Beats: 1
Warnings
Interest Coverage Ratio -13.3 is critical
Beneish M-Score 1.00 > -1.5 - likely earnings manipulation
Altman Z'' -15.00 < 1.0 - financial distress zone
Volatile Below Avwap Earnings
Tailwinds
Confidence
Precigen, Inc. (PGEN) is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases. The company utilizes two primary proprietary technology platforms: UltraCAR-T, designed for rapid chimeric antigen receptor T cell manufacturing, and AdenoVerse, which employs adenovectors for targeted gene delivery. Its current clinical pipeline includes candidates targeting ovarian cancer, acute myeloid leukemia, and HPV-positive solid tumors.
The biotechnology sector often utilizes a platform-based business model, where a single underlying technology can generate multiple distinct drug candidates, potentially diversifying clinical risk. Precigens UltraPorator device further supports this model by providing a proprietary hardware solution for the delivery of genetic material into cells. Investors may find it useful to review ValueRay for further data on clinical-stage biotech valuations. Formerly known as Intrexon Corporation, the company rebranded in 2020 to align its corporate identity with its focus on precision medicine and gene therapy integration.
- FDA approval path for PRGN-2012 determines near-term commercial revenue potential
- Clinical trial data readouts for UltraCAR-T platform drive investor sentiment
- Cash burn rate and liquidity levels impact future equity dilution risk
- Strategic partnerships for AdenoVerse platform influence long-term capital structure
- Regulatory milestones for PRGN-3005 and PRGN-3006 dictate oncology pipeline valuation
| Net Income: -204.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -1.38 > 0.02 and ΔFCF/TA -23.14 > 1.0 |
| NWC/Revenue: 255.0% < 20% (prev 1.44k%; Δ -1.19k% < -1%) |
| CFO/TA -0.83 > 3% & CFO -115.3m > Net Income -204.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.82 > 1.5 & < 3 |
| Outstanding Shares: last quarter (313.0m) vs 12m ago 6.50% < -2% |
| Gross Margin: 75.63% > 18% (prev -0.10%; Δ 7.57k% > 0.5%) |
| Asset Turnover: 23.63% > 50% (prev 3.26%; Δ 20.37% > 0%) |
| Interest Coverage Ratio: -13.29 > 6 (EBITDA TTM -86.3m / Interest Expense TTM 6.77m) |
| A: 0.58 (Total Current Assets 101.7m - Total Current Liabilities 21.1m) / Total Assets 138.6m |
| B: -16.95 (Retained Earnings -2.35b / Total Assets 138.6m) |
| C: -0.67 (EBIT TTM -90.0m / Avg Total Assets 133.7m) |
| D: -19.84 (Book Value of Equity -2.35b / Total Liabilities 118.4m) |
| Altman-Z'' = -76.79 = D |
| DSRI: 3.34 (Receivables 26.7m/1.06m, Revenue 31.6m/4.20m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.73 (AQ_t 0.14 / AQ_t-1 0.19) |
| SGI: 7.52 (Revenue 31.6m / 4.20m) |
| TATA: -0.64 (NI -204.4m - CFO -115.3m) / TA 138.6m) |
| Beneish M = 2.75 (Cap -4..+1) = D |
As of May 24, 2026, the stock is trading at USD 4.28 with a total of 2,155,050 shares traded.
Over the past week, the price has changed by -4.07%,
over one month by +7.07%,
over three months by +3.92% and
over the past year by +205.04%.
Precigen has received a consensus analysts rating of 3.75. Therefore, it is recommended to hold PGEN.
- StrongBuy: 1
- Buy: 2
- Hold: 0
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 11 | 157% |
P/S = 46.9405
P/B = 73.2931
Revenue TTM = 31.6m USD
EBIT TTM = -90.0m USD
EBITDA TTM = -86.3m USD
Long Term Debt = 93.2m USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.07m USD (from shortTermDebt, last quarter)
Debt = 103.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 5.12m
Net Debt = 47.1m USD (calculated: Debt 103.4m - CCE 56.2m)
Enterprise Value = 1.53b USD (1.48b + Debt 103.4m - CCE 56.2m)
Interest Coverage Ratio = -13.29 (Ebit TTM -90.0m / Interest Expense TTM 6.77m)
EV/FCF = -7.98x (Enterprise Value 1.53b / FCF TTM -191.8m)
FCF Yield = -12.53% (FCF TTM -191.8m / Enterprise Value 1.53b)
FCF Margin = -607.0% (FCF TTM -191.8m / Revenue TTM 31.6m)
Net Margin = -647.0% (Net Income TTM -204.4m / Revenue TTM 31.6m)
Gross Margin = 75.63% ((Revenue TTM 31.6m - Cost of Revenue TTM 7.70m) / Revenue TTM)
Gross Margin QoQ = 87.63% (prev 58.07%)
Tobins Q-Ratio = 11.04 (Enterprise Value 1.53b / Total Assets 138.6m)
Interest Expense / Debt = 6.55% (Interest Expense 6.77m / Debt 103.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -71.1m (EBIT -90.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.29 (Total Current Assets 101.7m / Total Current Liabilities 23.7m)
Debt / Equity = 5.11 (Debt 103.4m / totalStockholderEquity, last quarter 20.2m)
Debt / EBITDA = -0.55 (negative EBITDA) (Net Debt 47.1m / EBITDA -86.3m)
Debt / FCF = -0.25 (negative FCF - burning cash) (Net Debt 47.1m / FCF TTM -191.8m)
Total Stockholder Equity = 11.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -152.9% (out of range, set to none)
RoE = -8.66% (Net Income TTM -204.4m / Total Stockholder Equity 2.36b)
RoCE = -3.67% (EBIT -90.0m / Capital Employed (Equity 2.36b + L.T.Debt 93.2m))
RoIC = -74.18% (negative operating profit) (NOPAT -71.1m / Invested Capital 95.8m)
WACC = 6.39% (E(1.48b)/V(1.59b) * Re(6.47%) + D(103.4m)/V(1.59b) * Rd(6.55%) * (1-Tc(0.21)))
Discount Rate = 6.47% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 97.75 | Cagr: 10.71%
[DCF] Fair Price = unknown (Cash Flow -191.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.16 | # QB: 0
Revenue Correlation: 11.03 | Revenue CAGR: 8.74% | SUE: 1.57 | # QB: 1
EPS current Quarter (2026-06-30): EPS=-0.01 | Chg30d=N/A | Revisions=N/A | Analysts=2
EPS current Year (2026-12-31): EPS=-0.02 | Chg30d=+80.00% | Revisions=+20% | GrowthEPS=+98.5% | GrowthRev=+1187.2%
EPS next Year (2027-12-31): EPS=0.21 | Chg30d=+290.91% | Revisions=+33% | GrowthEPS=+1175.0% | GrowthRev=+94.8%
[Analyst] Revisions Ratio: +33%